Appl. No. 10/527,666

Atty. Dkt. No. 065691-0387

Amendments To The Claims:

1–12. (Canceled)

of antigenic sites or the antigenic density is low selected from the group consisting of hemolytic disease of the newborn, Sézary syndrome, chronic myeloid leukemia, leukemias, cancers in which the antigenic targets are weakly expressed, breast cancer, pathologies associated with the environment that target in particular individuals exposed to polychlorinated biphenyls, infectious diseases, tuberculosis, chronic fatigue syndrome (CFS), parasitic infections and schistosomula, comprising administering a an optimized human or humanized anti-HLA-DR monoclonal antibody, wherein said antibody as a general glycan structure is of the biantennary, type, with short chains, a low degree of syalylation, non-intercalated terminal attachment point mannoses and GlcNAcs, and a low degree of fucosylation and wherein the antibody is produced by rat myeloma YB2/0.

Claim 14. (Canceled)